Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients
F Denis, C Lethrosne, N Pourel… - JNCI: Journal of the …, 2017 - academic.oup.com
Background The use of web-based monitoring for lung cancer patients is growing in interest
because of promising recent results suggesting improvement in cancer and resource …
because of promising recent results suggesting improvement in cancer and resource …
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
…, K Auré, TA Szwebel, N Kramkimel, C Lethrosne… - Neurology, 2018 - AAN Enterprises
Objective To report the clinicopathologic features and outcome of myositis in patients treated
with immune checkpoint inhibitors (ICIs) (irMyositis). Methods We retrospectively analyzed …
with immune checkpoint inhibitors (ICIs) (irMyositis). Methods We retrospectively analyzed …
Overall survival in patients with lung cancer using a web-application-guided follow-up compared to standard modalities: Results of phase III randomized trial.
F Denis, C Lethrosne, N Pourel, O Molinier… - 2016 - ascopubs.org
LBA9006 Background: We developed a web-application for an early detection of symptomatic
relapse, complications and early supportive care in high-risk lung cancer patients …
relapse, complications and early supportive care in high-risk lung cancer patients …
Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (PRO) vs. routine surveillance in lung cancer patients: final results.
6500 Background: In a previous interim analysis, we found a 7-month median overall survival
(OS) benefit (p = 0.002) associated with web-based monitoring to detect recurrence in lung …
(OS) benefit (p = 0.002) associated with web-based monitoring to detect recurrence in lung …
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504
…, S Friard, F Barlesi, C Lethrosne… - European …, 2015 - Eur Respiratory Soc
The IFCT-0504 phase II trial evaluated the efficacy of erlotinib versus carboplatin–paclitaxel
(CP) as first-line treatment in 130 cases of advanced lepidic-predominant adenocarcinoma (…
(CP) as first-line treatment in 130 cases of advanced lepidic-predominant adenocarcinoma (…
Immune-mediated necrotizing myositis in patients receiving immune checkpoint inhibitors: clinical and histopathological features, treatment and outcome (N6. 002)
…, K Auré, TA Szwebel, N Kramkimel, C Lethrosne… - 2018 - AAN Enterprises
Objective: To assess the clinical, histopathologic features and outcome of myositis triggered
by immune checkpoint inhibitors (ICIs). Background: Myositis has been recently recognized …
by immune checkpoint inhibitors (ICIs). Background: Myositis has been recently recognized …
Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer
Methods| As described previously, 2 in this randomized trial, patients with advanced
nonprogressive stage IIA (TXN1) to IV lung cancer were randomly assigned within 3 months of …
nonprogressive stage IIA (TXN1) to IV lung cancer were randomly assigned within 3 months of …
Production and diffusion of axes in the Seine valley
F Giligny, F Bostyn, J Couderc, H Lethrosne… - Stone Axe Studies …, 2011 - torrossa.com
… Over much of this time, work on several of these fronts was both undertaken and/or
encouraged by Claire Fell, who effectively established the baseline from which much recent work …
encouraged by Claire Fell, who effectively established the baseline from which much recent work …
European lung corner
E Bel, JP Sculier, A Navarro-Torné, M Vidal… - Eur Respiratory Soc
46-5 Contents.indd Page 1 CONTENTS VOLUME 46 / NUMBER 5 / NOVEMBER 2015
EDITORIALS 1227 The quest for the grail: multidimensional efforts for understanding and …
EDITORIALS 1227 The quest for the grail: multidimensional efforts for understanding and …
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
S Suzuki, N Ishikawa, F Konoeda, N Seki… - Neurology, 2017 - AAN Enterprises
Objective: To report the clinical features of myasthenia gravis (MG) induced by treatment
with immune checkpoint inhibitors using 2-year safety databases based on postmarketing …
with immune checkpoint inhibitors using 2-year safety databases based on postmarketing …